Asthma

A longitudinal study aims to identify which children with asthma are more likely to suffer a loss of lung function.

Repurposing Gleevec as an asthma drug is one of the possibilities that the PrecISE trial of severe asthma is examining. The trial has an adaptive design.

Infants exposed to acid reducers may have an increased risk of developing asthma and recurrent wheeze in childhood.

Secretions of fibroblast growth factor (FGF) and granulocytic colony-stimulating growth factor (G-CSF) in airway epithelium may be to blame.

Using biomarkers for tailoring asthma treatment can reduce the frequency of asthma exacerbations. Some recent results suggest that eosinophil-guided asthma management is associated with lower annual costs than FeNO-guided management.

The Patient-Centered Outcomes Research Institute (PCORI) has approved an award for the American Academy of Family Physicians (AAFP) of $31 million to fund a large comparative study of asthma treatments.

Asthma becomes more prevalent in females than males in puberty. Researchers have hypothesized that sex hormones may play a significant role in the manifestation of asthma symptoms.

Six biologics are on the market and more are in the pipeline. Biologics target the inflammatory cytokines involved in the pathogenesis of asthma.

Thymic stromal lymphopoietin (TSLP) has been identified as starting the cascades of cytokines that result in the inflammation that underlies many cases of severe asthma. A review paper discusses how Tezspire inhibits TSLP and the evidence for its safety and efficacy in numerous clinical trials.

University of North Carolina researchers report that interleukin-13, responsible for inflammation and severe asthma symptoms, may have properties that fend off the SARS-CoV-2 virus that causes COVID-19.

But researchers find that fewer than 1 in 4 children and young adults had follow-up visits.

California’s “in lieu of services” (ILOS) program includes asthma remediation services such as dehumidifiers, improved ventilation and mold removal.

Genentech researchers identify oncostatin M as a protein that may be responsible for the severe airway inflammation seen in patients with noneosinophilic asthma.

Real-world study conducted in Japan shows Dupixent (dupilumab) reduced the number of annual severe asthma exacerbations by 53%. There were some reports of adverse events associated with high eosinophil levels in patients who switched to Dupixent after taking a different biologic.

Xolair (omalizumab), Fasenra (benralizumab), Dupixent (dupilumab) and Nucala (mepolizumab) can now be self-administered.

Research of the real-world effect of asthma interventions among Black and Latino patients is limited. Findings reported in the New England Journal of Medicine will help fill that void.

Despite missing the primary end point of significantly reducing oral corticosteroid dose, patients with asthma on Tezspire in the SOURCE trial received other benefits from the drug.

Pediatric severe asthma is a heterogeneous disease and based on data, a multi-disciplinary approach can improve the diagnosis and management of these children.

Five phenotype clusters were discovered to be associated with the exacerbation, or worsening, of chronic inflammatory airway diseases of asthma and chronic obstructive pulmonary disease (COPD), according to a recent study published in PLOS ONE.

FDA approves first generic of Symbicort for asthma and COPD and first therapy for rare seizure disorder, Rinvoq and Lynparza get nods for new indications, the agency approves a new delivery system for Alzheimer’s therapy, regulators extend review for Opzelura for skin condition and issue CRL for Fasenra for chronic rhinosinusitis.

Non-hospitalized symptomatic COVID-19 patients who were treated with ciclesonide to alleviate early symptoms did not see any difference in results compared to patients who were treated with a placebo of the drug.

Young adults with asthma were recently surveyed on their preparation of the transition to adult asthma care. Half of all those surveyed did not remember being introduced to concepts of transitioning care, including asthma self-management, by their pediatric asthma provider.

Psoriasis medicine containing risankizumab, worsened symptoms in patients with severe asthma.